Novo Nordisk’s ‘Super Ozempic’ Trial Disappoints Again
The drugmaker’s shares dropped after releasing weaker-than-expected trial results for next generation drug CagriSema, which failed to outperform Eli Lilly’s Mounjaro.
The drugmaker’s shares dropped after releasing weaker-than-expected trial results for next generation drug CagriSema, which failed to outperform Eli Lilly’s Mounjaro.
